Compare VICI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VICI | RVMD |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7B | 30.1B |
| IPO Year | 2017 | N/A |
| Metric | VICI | RVMD |
|---|---|---|
| Price | $26.83 | $189.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $33.75 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 5.8M | 2.1M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | ★ 1.95 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $4,006,116,000.00 | N/A |
| Revenue This Year | $4.47 | N/A |
| Revenue Next Year | $1.67 | $533.02 |
| P/E Ratio | $32.62 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $25.82 | $34.00 |
| 52 Week High | $34.01 | $194.56 |
| Indicator | VICI | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.15 | 60.66 |
| Support Level | $25.95 | $176.00 |
| Resistance Level | $27.50 | $193.83 |
| Average True Range (ATR) | 0.45 | 6.99 |
| MACD | 0.08 | -1.05 |
| Stochastic Oscillator | 57.22 | 65.41 |
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment and leisure destinations, subject to long-term triple net leases. It own nearly 93 experiential assets across a geographically portfolio consisting of nearly 54 gaming properties and nearly 39 other experiential properties across the United States and Canada, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.